News and Events

Subscribe to our press distribution list to receive the latest news about AMW.

Upcoming

Events

No events available

Past

Events

Archive

Pharmapack

January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/

Pharmasynergy

February 08-09, 2024
London, UK

euroPLX84

February 26-27, 2024 Lisbon, Portugal

BIO-Europe Spring

March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/

4th Wet AMD & Diabetic Eye Disease Drug Development

March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/

BIO International Convention

June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention

CPHI South East Asia

July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html

CPHI 2024

October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html

PODD – Partnership Opportunities in Drug Delivery

October 28-29, 2024 Boston, USA https://poddconference.com

BIO-Europe

November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/

Latest

News

9. January 2023

AMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.

22. December 2022

Further EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.

25. October 2022

AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.

10. August 2022

AMW Strengthens Management Team to Support the Company’s Growth Strategy

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.

13. July 2022

Further marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central America. AMW’s goserelin implant is the only approved generic implant version to date for AstraZeneca’s originator product Zoladex®1. Goserelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate or breast cancer, as well as certain gynecological diseases. AMW’s goserelin implant is now available to patients in approximately 30 countries worldwide as a cost-effective alternative therapy.

For press and news inquiries please send an e-mail to news@a-m-w.eu